Common use of Additional Grant Information Clause in Contracts

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700011 HEALTH AND HUMAN SERVICES COMMISSION RECOVERY RESOURCE COUNCIL ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH Date of execution: _July 21, 2020 ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Chief Executive Officer Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 21, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700011 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers.HHS0006637 ATTACHMENTS FOLLOW C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.SECTION I: PURPOSE

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700188 HEALTH AND HUMAN SERVICES COMMISSION AUSTIN RECOVERY, INC. ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleCEO Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 31, 2020 Date of Executionexecution: Augusk July 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700188 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 H79TI081729 Federal Award Date: April 23, 2020 09/30/2018 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: State Opioid Response, 93.788 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 AtlantaOfficer, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: Point of Contact is ▇▇▇▇▇▇▇▇ ▇. Browne, Grants Specialist, Contact Number: (▇▇▇ Printed Name▇) ▇▇▇-▇▇▇▇, Email: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. The email “Subject Line” and the name HHS000663700078 HEALTH AND HUMAN SERVICES COMMISSION ALTERNATIVE OPIATE TREATMENT PROGRAM, LLC ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Owner Date of the attached file for all reports should be clearly identified with the Grantee’s Nameexecution: _August 17, Contract Number2020 Date of execution: August 17, IDCU/COVID and the month the report covers. C. May use funds to pay pre2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000663700078 ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak responseGRANTEE VERSION 2.16.1 ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I SYSTEM AGENCY SOLICITATION NO. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligibleHHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A MEDICATION ASSISTED TREATMENT

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700174 HEALTH AND HUMAN SERVICES COMMISSION MHMR OF TARRANT COUNTY ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor , CEO Date of Executionexecution: September 3July 29, 2020 Date of Executionexecution: Augusk 31July 29, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700174 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700142 HEALTH AND HUMAN SERVICES COMMISSION GULF COAST CENTER ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3August 2, 2020 Date of Executionexecution: Augusk 31July 29, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700142 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700056 HEALTH AND HUMAN SERVICES COMMISSION Human Services of Southeast Texas dba ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 AtlantaAssoc. Commissioner IDD/BH Date of execution: _July 20, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇2020 ▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700056 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700018 SYSTEM AGENCY GRANTEE Signature g g Printed Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Title: _Assistant Deputy Commissioner Printed Name: ▇▇▇▇ Printed Name: Signature Emi1y Everekke ▇▇▇▇ Title: _Deputy Commissioner Program Direckor Ector County Judge Date of Execution: September 3August 19, 2020 Date of Execution: Augusk 31August 6, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700018 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 6 NU58DP006501-01-03 Federal Award Date: April 23, 2020 2/26/2019 Name of Federal Awarding Agency: Centers for of Disease Control and Prevention CFDA Name and Number: 93.439 Awarding Official Contact Information: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇@▇▇▇▇.▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed HHS000494700001 DEPARTMENT OF STATE HEALTH SERVICES TEXAS CHAPTER OF AMERICAN PLANNING ASSOCIATION, INC. By: By: ▇▇▇▇▇ ▇▇▇▇, M.D Name: :▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed NameAssociate Commissioner, Community Health ImprToivtleem: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Eexnetcutive Administrator Date of Executionsignature: September 316, 2020 2019 Date of Executionsignature: Augusk 31September 14, 2020 2019 THE FOLLOWING ATTACHMENTS DOCUMENTS ARE ATTACHED TO SYSTEM AGENCY THIS CONTRACT NO. HHS000812700039 SIGNATURE DOCUMENT AND THEIR RESPECTIVE TERMS ARE HEREBY INCORPORATED BY REFERENCEINTO THE CONTACT: ATTACHMENT A - -- STATEMENT OF WORK ATTACHMENT B - -- BUDGET ATTACHMENT C - – HHSC UNIFORM TERMS AND CONDITIONS - CONDITIONS, VERSION 2.15-GRANT ATTACHMENT D - –SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS -- DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW F – FFATA CERTIFICATION ATTACHMENT G -- FEDERAL ASSURANCES-NON-CONSTRUCTION PROGRAMS I. GRANTEE RESPONSIBILITIES Grantee will:RESPONSIBILITIES A. Enhance laboratory testing Coordinate participation to advance the Plan4Health initiative. Grantee must convene public health and reporting capacityplanning partners through the Planners4Health regional roundtable model in collaboration with Texas Public Health Association (“TPHA”). The Planners4Health roundtables will create regional, cross-disciplinary taskforces to implement land-use interventions that support physical activity (“PA”) through activity- friendly routes. Key outcomes include: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens Municipal/Regional planning policies and/or comprehensive planning documents that can be tested at the jurisdiction’s incorporate public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratoryconcepts and support physical activity through bike/pedestrian paths and general improvements to connectivity. 2. Screen for past infection (e.g.Collect, serology) for health care workers, employees of high-risk facilities, critical infrastructure workforcereview, and childcare providersassess for strengths and weaknesses of the Active Living Plans developed by DSHS partners from the Texas Healthy Communities (“TXHC”) program. Provide recommendations and resources for DSHS or TXHC, or both, communities to address implementation barriers and improve program documents. Key outcomes include: a. An analysis in report form of frequent barriers faced by TXHC communities with suggestions on how best to address these, which can be used to improve guidance offered to current and future TXHC partners. 3b. Revision of the Active Living/Physical Activity Plan Template ▇. Obtain all jurisdictional laboratory test data electronically▇▇▇▇▇▇▇, including from new, non-traditional testing settings, complete and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – submit a Project Work Plan and related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily budget to DSHS. Data The Work Plan and budget must meet new federal Coronavirus AID, Relief, contain and Economic Security (CARES) Act laboratory guidanceaddress activities that support TXPAN strategies as well as staff/organizational responsibility and timeframe. All public health data A Project Work Plan Draft must be reported electronically reviewed and approved by DSHS prior to the final version submission date. The draft Project Work Plan and budget draft must be submitted to DSHS in compliance with on or before sixty days after execution of the Texas Administrative Code contract and within appropriate reporting timeframesthe final Project Work Plan and budget submission is due to DSHS on or before ninety days after execution. B. Submit ▇. ▇▇▇▇▇▇▇ and submit an Evaluation Plan to DSHS. An Evaluation Plan Draft must be reviewed and approved by DSHS prior to the final version submission date. The Evaluation Plan Draft must be submitted within sixty days of contract execution and the final Evaluation Plan submission is due to DSHS within ninety days of contract execution. Evaluation reports will be due to DSHS on a quarterly basis thereafter. D. Participate in monthly report on the report template feedback calls (monthly project status reports) with DSHS Program to be provided by the DSHS. Monthly reports are due conducted on or before the 15th of each monthmonth of the contract term, unless otherwise agreed to in writing by DSHS. Each report must contain a summary of activities that occurred during On the preceding month for each activity listed above in Section I Acalls, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and ▇ will discuss the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used forfollowing: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative bodyImplementation status; 2. The salary or expenses of any grant or contract recipientBarriers and methods to address those barriers; 3. Opportunities to enhance the activities; 4. Lessons learned; and 5. Next steps. Other calls may be added, or agent acting for such recipientas appropriate, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative bodywith Performing Agency and DSHS Program.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 1 NU90TP921945-01-00 Federal Award Date: April 23, 2020 7/3/2018 Name of Federal Awarding Agency: Centers for Disease Control and Prevention CFDA Number: 93.354 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ 30333 Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY DEPARTMENT OF STATE HEALTH SERVICES CONTRACT NO. HHS000812700039 SYSTEM AGENCY HHS000371500017 DSHS GRANTEE Signature Printed Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇, MD Name: ▇▇ ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Title: County Judge Date of Executionexecution: September 3, 2020 Date of Executionexecution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000371500017 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - – BUDGET ATTACHMENT B-1 – INDIVIDUAL PROJECT BUDGET(S) ATTACHMENT C - HHSC UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - CONTRACT AFFIRMATIONS ATTACHMENT E - DSHS SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E F - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING AND LOBBYING FORM ATTACHMENT G - FFATA CERTIFICATION ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will:RESPONSIBILITIES A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above Complete the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to Hurricane ▇▇▇▇▇▇ Crisis Project (HHCP) by performing activities for this project that support the Public Health Crisis Response Cooperative Agreement for Emergency Response (Funding Opportunity Number CDC-RFA-TP18-1802) from the Centers for Disease Control and Prevention (CDC).▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name B. Work to improve or strengthen one or more of the attached file following objectives in accordance with their approved workplan (See para. C, below, for all reports should be clearly identified with the more information on Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.workplan requirements):

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700012 SYSTEM AGENCY GRANTEE Signature g Printed Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Printed Name: ▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Assistant Deputy Commissioner Program Direckor Title: _Mayor Date of Execution: September 3August 17, 2020 Date of Execution: Augusk 31July 17, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700012 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR HHSC CONTRACT NO. HHS000663700098 HEALTH AND HUMAN SERVICES COMMISSION UNLIMITED VISIONS AFTERCARE, INC ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ PhoneAssoc. Commissioner IDD/BH Title: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CEO Date of execution: July 20, 2020 Date of execution: July 20, 2020 THE FOLLOWING ATTACHMENTS TO HHSC CONTRACT NO. HHS000812700039 SYSTEM AGENCY HHS000663700098 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE Signature Printed Name: ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT ’S PROPOSAL FOR SOLICITATION NO. HHS000812700039 ARE INCORPORATED BY REFERENCEHHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will:TREATMENT FOR YOUTH A. Enhance laboratory testing and reporting capacity: Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-The below service types/levels of care are based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the on Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on (TAC) requirements, as referenced in the report template to be provided by Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to following link: ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral- health-services-providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; Outpatient Treatment Services 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Supportive Residential Treatment Services 3. Intensive Residential Treatment Services B. TREATMENT FOR YOUTH (TRY) Program Target Population

Additional Grant Information. DSHS System Agency Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic NH75OT000045 Assistance (CFDA) Listing Name and Number Number: Activities to Support State, Tribal, Local and Territorial (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELCSTLT) – 93.323 Health Department Response to Public Health or Healthcare Crises; 93.391 Federal Award Date: April 23May 26, 2020 2021 Federal Award Project Period through May 31, 2023 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ – Mailstop TV2 Atlanta, GA Email: ▇▇▇▇▇-@▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600035 SYSTEM AGENCY GRANTEE Signature Signature Printed Name: ▇▇▇▇ Co1e Printed Name: ▇▇▇▇▇▇▇▇ ▇ _▇▇▇▇ Printed Name: Signature Emi1y Everekke ▇▇▇▇, ▇▇. Title: _Deputy Depuky Commissioner Program Direckor Date of ExecutionTitle: September 3, 2020 Chief Execukive Officer Date of Execution: Augusk 3119, 2020 2021 Date of Execution: Augusk 18, 2021 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600035 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - A: STATEMENT OF WORK ATTACHMENT B - B: BUDGET ATTACHMENT C - C: HHS UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS D: HHS CONTRACT AFFIRMATIONS ATTACHMENT E - E: FEDERAL ASSURANCES NON-CONSTRUCTION AND CERTIFICATIONS ATTACHMENT F - CERTIFICATION REGARDING LOBBYING F: FFATA FORM ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) G: INDIRECT COST RATE ACKNOWLEDGMENT LETTER- TEN PERCENT DE MINIMUS ATTACHMENTS FOLLOW FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will:RESPONSIBILITIES A. Enhance laboratory testing and reporting capacity: 1Submit a workplan within 30 days of contract effective date to System Agency outlining how required activities will be accomplished. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above System Agency must approve the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratoryworkplan before Grantee begins activities with targeted communities. 2B. Identify Grantee staff (new and existing) who will be leads for the Contract. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) Any changes to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data these staff members must be reported electronically to DSHS System Agency in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report coversprogram report. C. May use funds to pay pre-award costs which date back to January 20, 2020, Identify and target communities disproportionately impacted by COVID-19. Grantee will specify how the target communities were identified and report the disproportionately impacted communities that are directly related to will be targeted in the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHSGrantee workplan. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used forEngage targeted communities disproportionately impacted by COVID-19 through: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700026 SYSTEM AGENCY GRANTEE Signature Signature Printed Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Title: _Assistant Deputy Commissioner Printed Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Health & Senior Services Manager Date of Execution: September 3July_27, 2020 Date of Execution: Augusk 31July_26, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700026 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700279 HEALTH AND HUMAN SERVICES COMMISSION SERVING CHILDREN AND ADULTS IN NEED, INC. ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH Date of execution: _August 13, 2020 Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Chief Executive Officer Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31August 12, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700279 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS System Agency Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic NH75OT000045 Assistance (CFDA) Listing Name and Number Number: Activities to Support State, Tribal, Local and Territorial (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELCSTLT) – 93.323 Health Department Response to Public Health or Healthcare Crises; 93.391 Federal Award Date: April 23May 26, 2020 2021 Federal Award Project Period through May 31, 2023 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ – Mailstop TV2 Atlanta, GA Email: ▇▇▇▇▇-@▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600025 SYSTEM AGENCY GRANTEE Signature Signature Printed Name: ▇▇▇▇ Co1e Printed Name: ▇▇▇▇▇▇▇ ▇▇ . ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Depuky Commissioner Program Direckor Date of ExecutionTitle: September 3, 2020 Hida1go Counky Judge Date of Execution: Augusk 3130, 2020 2021 Date of Execution: Augusk 27, 2021 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600025 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - A: STATEMENT OF WORK ATTACHMENT B - B: BUDGET ATTACHMENT C - C: HHS UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS D: HHS CONTRACT AFFIRMATIONS ATTACHMENT E - E: FEDERAL ASSURANCES NON-CONSTRUCTION AND CERTIFICATIONS ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - F: FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) FORM ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES To ensure community engagement in targeted communities disproportionately impacted by COVID-19 and the building of sustainable relationships in those targeted communities, Grantee willwill conduct the following activities: A. Enhance laboratory testing and reporting capacity: 1Submit a workplan within 30 days of contract effective date to System Agency outlining how required activities will be accomplished. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above System Agency must approve the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratoryworkplan before Grantee begins activities with targeted communities. 2B. Identify Grantee staff (new and existing) who will be leads for the Contract. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) Any changes to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data these staff members must be reported electronically to DSHS System Agency in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report coversprogram report. C. May use funds to pay pre-award costs which date back to January 20, 2020, Identify and target communities disproportionately impacted by COVID-19. Grantee will specify how the target communities were identified and report the disproportionately impacted communities that are directly related to will be targeted in the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHSGrantee workplan. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used forEngage targeted communities disproportionately impacted by COVID-19 through: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI08354-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700010 HEALTH AND HUMAN SERVICES COMMISSION CENIKOR FOUNDATION Name: ▇▇▇▇▇ Ita Name: ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Associate Commissioner Program Direckor President/CEO Date of Executionexecution: September 3_July 23, 2020 Date of Executionexecution: Augusk 31July 23, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700010 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700083 HEALTH AND HUMAN SERVICES COMMISSION LIBERTY LODGE ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NOAssoc. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: Commissioner IDD/BH ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Executive Director Date of Executionexecution: September 3July 19, 2020 Date of Executionexecution: Augusk 31July 19, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700083 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: Substance Abuse and Prevention Treatment (SAPT), 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700080 HEALTH AND HUMAN SERVICES COMMISSION WTCR ABILENE, INC. ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 AtlantaAssoc. Commissioner IDD/BH Date of execution: _July 21, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇2020 ▇▇▇▇ ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor MD President Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 21, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700080 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE VERSION 2.16.1 ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A MEDICATION ASSISTED TREATMENT

Additional Grant Information. DSHS A. Grantee Data Universal Numbering System (DUNS) Number: 807391511 806781373 B. Federal Award Identification Number (▇▇▇▇): NU50CK000501 2001TXSRAE C. Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 • Name - Number: State Sexual Risk Avoidance Education - 93.235 D. Federal Award Date: April 2316, 2020 2020 E. Federal Award Period: 10-1-2019 to 9-30-2021 F. Name of Federal Awarding Agency: Centers Administration for Disease Control Children and Prevention Awarding Official Contact InformationFamilies Signature Printed Name: ▇▇▇ ▇▇▇▇▇ Title: _Deputy Executive Commissioner Date of ExecutMioany: 16, 2021 Signature Printed Name: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Executive Director Date of Execution: September 3May 15, 2020 Date 2021 EXHIBITS: Exhibit A: HHS Solicitation Affirmations 2.16.1 Exhibit C-1: Assurances - Non-Construction Programs Exhibit C-2: Certification Regarding Lobbying Exhibit D: Signed Legislative Assurances Exhibit E: Signed Assurance Regarding Non-Affiliation Requirement Exhibit F: Evaluation Score Tool Exhibit G: Exceptions Form (if applicable) Exhibit H: Federal Funding Accountability and Transparency Act (FFATA) Certification FORMS: Form A: Respondent Information Face Page Form A-1: Grant Application for RFA HHS0009661 Form B: Texas Counties and Regions Form C: Contact Person Information Form D: Financial Management and Administrative Questionnaire Form E: Government Entity (if applicable) Form E-1: Non-Profit or For-Profit Entity (if applicable) Form F: Curriculum Implementation Plan Form G: Curriculum Site Letter of ExecutionParticipation Agreement Form H: Augusk 31Service Learning Implementation Plan Form I: Budget Summary DocuSign Envelope ID: F8CBE454-2FD1-402D-AF7F-50DCAF26AE20 Solicitation RFA HHS0009661 HHSC Uniform Terms and Conditions Version 2.16.1 Published and Effective: March 26, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE2019 Responsible Office: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Chief Counsel

Additional Grant Information. DSHS System Agency Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic NH75OT000045 Assistance (CFDA) Listing Name and Number Number: Activities to Support State, Tribal, Local and Territorial (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELCSTLT) – 93.323 Health Department Response to Public Health or Healthcare Crises; 93.391 Federal Award Date: April 23May 26, 2020 2021 Federal Award Project Period through May 31, 2023 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ – Mailstop TV2 Atlanta, GA Email: ▇▇▇▇▇-@▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600013 SYSTEM AGENCY GRANTEE Signature Signature Printed Name: ▇▇▇▇ Co1e Printed Name: Judge ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Depuky Commissioner Program Direckor Date of ExecutionTitle: September 3, 2020 Counky Judge Date of Execution: Augusk 3127, 2020 2021 Date of Execution: Augusk 26, 2021 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600013 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - A: STATEMENT OF WORK ATTACHMENT B - B: BUDGET ATTACHMENT C - C: HHS UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS D: HHS CONTRACT AFFIRMATIONS ATTACHMENT E - E: FEDERAL ASSURANCES NON-CONSTRUCTION AND CERTIFICATIONS ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - F: FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) FORM ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES To ensure community engagement in targeted communities disproportionately impacted by COVID-19 and the building of sustainable relationships in those targeted communities, Grantee willwill conduct the following activities: A. Enhance laboratory testing and reporting capacity: 1Submit a workplan within 30 days of contract effective date to System Agency outlining how required activities will be accomplished. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above System Agency must approve the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratoryworkplan before Grantee begins activities with targeted communities. 2B. Identify Grantee staff (new and existing) who will be leads for the Contract. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) Any changes to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data these staff members must be reported electronically to DSHS System Agency in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report coversprogram report. C. May use funds to pay pre-award costs which date back to January 20, 2020, Identify and target communities disproportionately impacted by COVID-19. Grantee will specify how the target communities were identified and report the disproportionately impacted communities that are directly related to will be targeted in the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHSGrantee workplan. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used forEngage targeted communities disproportionately impacted by COVID-19 through: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700019 SYSTEM AGENCY GRANTEE Signature Signature Printed Name: _▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Title: _Assistant Deputy Commissioner Date of Execution: _August 27, 2020 Printed Name: _KP ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor County Judge Date of Execution: September 3, 2020 Date of Execution: Augusk 31_August 27, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700019 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700162 HEALTH AND HUMAN SERVICES COMMISSION UNLIMITED VISIONS AFTERCARE, INC. ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH Date of execution: _July 20, 2020 ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700162 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: HHS000663700004 HEALTH AND HUMAN SERVICES COMMISSION SWINNCOMM HOLDINGS LLC ▇▇▇▇▇ Ita ▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssociate Commissioner Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 24, 2020 Date of Executionexecution: Augusk 31July 24, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700004 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700168 HEALTH AND HUMAN SERVICES COMMISSION PLAINVIEW SERENITY CENTER, INC. ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 AtlantaAssoc. Commissioner IDD/BH Date of execution: _July 20, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇2020 ▇▇▇▇ ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700168 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700201 HEALTH AND HUMAN SERVICES COMMISSION CENIKOR FOUNDATION Name:▇▇▇▇▇ Ita Name: ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Executionexecution: September 3July 24, 2020 Date of Executionexecution: Augusk 31July 24, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700201 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700253 HEALTH AND HUMAN SERVICES COMMISSION CENIKOR FOUNDATION Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssoc. Commissioner IDD/BH President/CEO Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 24, 2020 Date of Executionexecution: Augusk 31July 24, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700253 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS System Agency Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic NH75OT000045 Assistance (CFDA) Listing Name and Number Number: Activities to Support State, Tribal, Local and Territorial (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELCSTLT) – 93.323 Health Department Response to Public Health or Healthcare Crises; 93.391 Federal Award Date: April 23May 26, 2020 2021 Federal Award Project Period through May 31, 2023 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ – Mailstop TV2 Atlanta, GA Email: ▇▇▇▇▇-@▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600015 SYSTEM AGENCY GRANTEE Signature Signature Printed Name: ▇▇▇▇ Co1e Printed Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Depuky Commissioner Program Title: Medica1 Direckor Date of Execution: September 3Augusk 26, 2020 2021 Date of Execution: Augusk 3126, 2020 2021 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS001057600015 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - A: STATEMENT OF WORK ATTACHMENT B - B: BUDGET ATTACHMENT C - C: HHS UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS D: HHS CONTRACT AFFIRMATIONS ATTACHMENT E - E: FEDERAL ASSURANCES NON-CONSTRUCTION AND CERTIFICATIONS ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - F: FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) FORM ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES To ensure community engagement in targeted communities disproportionately impacted by COVID-19 and the building of sustainable relationships in those targeted communities, Grantee willwill conduct the following activities: A. Enhance laboratory testing and reporting capacity: 1Submit a workplan within 30 days of contract effective date to System Agency outlining how required activities will be accomplished. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above System Agency must approve the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratoryworkplan before Grantee begins activities with targeted communities. 2B. Identify Grantee staff (new and existing) who will be leads for the Contract. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) Any changes to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data these staff members must be reported electronically to DSHS System Agency in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report coversprogram report. C. May use funds to pay pre-award costs which date back to January 20, 2020, Identify and target communities disproportionately impacted by COVID-19. Grantee will specify how the target communities were identified and report the disproportionately impacted communities that are directly related to will be targeted in the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHSGrantee workplan. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used forEngage targeted communities disproportionately impacted by COVID-19 through: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name, Email: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇@▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR HHSC CONTRACT NO. HHS000663700195 HEALTH AND HUMAN SERVICES COMMISSION ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ Ita Associate Commissioner ▇▇▇▇▇ ▇▇▇▇▇▇ Clinical Director/Owner Date of execution: July 20, 2020 Date of execution: July 18, 2020 THE FOLLOWING ATTACHMENTS TO HHSC CONTRACT NO. HHS000663700195 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR YOUTH A. Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral- health-services-providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; Outpatient Treatment Services 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Supportive Residential Treatment Services 3. Intensive Residential Treatment Services B. TREATMENT FOR YOUTH (TRY) Program Target Population

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed HHS000663700044 HEALTH AND HUMAN SERVICES COMMISSION CLEAN INVESTMENTS INC Name: ▇▇▇▇▇ Ita Name: ▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssociate Commissioner Director Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 27, 2020 Date of Executionexecution: Augusk 31July 27, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700044 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name, Email: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. The email “Subject Line” HHS000779500005 HEALTH AND HUMAN SERVICES COMMISSION CITY OF LUBBOCK ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH Name: Title: ▇▇▇ ▇▇▇▇ Mayor Date of execution: July 30, 2020 Date of execution: July 30, 2020 THE FOLLOWING DOCUMENTS ARE HEREBY ATTACHED TO SYSTEM AGENCY CONTRACT NO. HHS000779500005: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENTS FOLLOW To provide adjunct services to clients with co-occurring psychiatric and the name of the attached file substance use disorders (COPSD), emphasizing integrated treatment for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID both mental health needs and the month the report coverssubstance use disorders. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: HHS000663700060 HEALTH AND HUMAN SERVICES COMMISSION SOUTH TEXAS SUBSTANCE ABUSE RECOVERY SERVICES, INC. ▇▇▇▇▇ Ita Associate Commissioner ▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700060 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700159 HEALTH AND HUMAN SERVICES COMMISSION DALLAS SIGMA COUNSELING SERVICES, INC. _ _ ▇▇▇▇▇ ▇Ita Associate Commissioner Date of execution: _July 20, 2020 ▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700159 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 H79TI081729 Federal Award Date: April 23, 2020 09/30/2018 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: State Opioid Response, 93.788 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇▇▇▇ ▇. Browne, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Email: SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700087 HEALTH AND HUMAN SERVICES COMMISSION ADULT REHABILITATION SERVICES, INC. Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssoc. Commissioner IDD/BH Sponsor Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3August 20, 2020 Date of Executionexecution: Augusk 31August 17, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700087 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE VERSION 2.16.1 ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A MEDICATION ASSISTED TREATMENT

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed HHS000663700108 HEALTH AND HUMAN SERVICES COMMISSION ABODE TREATMENT, INC. Name: ▇▇▇▇▇ Ita Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title▇, ▇▇. Associate Commissioner President & Chief Executive Officer Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700108 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700129 HEALTH AND HUMAN SERVICES COMMISSION SERVING CHILDREN AND ADULTS IN NEED, INC. ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleChief Executive Officer Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700129 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700045 HEALTH AND HUMAN SERVICES COMMISSION BLUEBONNET TRAILS COMMUNITY MHMR CENTER Name: ▇▇▇▇▇ ▇▇▇▇▇▇ Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NOAssoc. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor IDD/BH Executive Director Date of Executionexecution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700045 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT GOV’T ENTITY VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700189 HEALTH AND HUMAN SERVICES COMMISSION THE GULF COAST CENTER Assoc. Commissioner IDD/BH Date of execution: _July 29, 2020 ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 29, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700189 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR HHSC CONTRACT NO. HHS000663700259 HEALTH AND HUMAN SERVICES COMMISSION CENTRAL PLAINS CENTER MHMR ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH ▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 AtlantaCEO Date of execution: _July 20, GA ▇▇▇▇▇-▇▇▇▇ Phone2020 Date of execution: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY July 20, 2020 THE FOLLOWING ATTACHMENTS TO HHSC CONTRACT NO. HHS000812700039 SYSTEM AGENCY HHS000663700259 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE Signature Printed Name: ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT ’S PROPOSAL FOR SOLICITATION NO. HHS000812700039 ARE INCORPORATED BY REFERENCEHHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will:TREATMENT FOR YOUTH A. Enhance laboratory testing and reporting capacity: Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-The below service types/levels of care are based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the on Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on (TAC) requirements, as referenced in the report template to be provided by Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to following link: ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral- health-services-providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; Outpatient Treatment Services 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Supportive Residential Treatment Services 3. Intensive Residential Treatment Services B. TREATMENT FOR YOUTH (TRY) Program Target Population

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: HHS000663700016 HEALTH AND HUMAN SERVICES COMMISSION LONGVIEW WELLNESS ▇▇▇▇▇ Ita ▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Associate Commissioner Program Direckor Chief Executive Officer Date of Executionexecution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 17, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700016 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700014 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Signature Printed Name: Title: Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700014 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700054 HEALTH AND HUMAN SERVICES COMMISSION YSLETA DEL SUR PUEBLO ▇▇▇▇▇ Ita Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssociate Commissioner Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 21, 2020 Date of Executionexecution: Augusk 31July 21, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700054 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700111 HEALTH AND HUMAN SERVICES COMMISSION PLAINVIEW SERENITY CENTER, INC. ▇▇▇▇▇ Ita Associate Commissioner Dr. ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleCEO Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700111 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name, Email: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇@▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR HHSC CONTRACT NO. HHS000663700275 HEALTH AND HUMAN SERVICES COMMISSION PHOENIX HOUSES OF TEXAS, INC. Name: ▇▇▇▇▇ ▇▇▇▇▇▇ Name: ▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH President & CEO Date of execution: _August 12, 2020 Date of execution: August 12, 2020 THE FOLLOWING ATTACHMENTS TO HHSC CONTRACT NO. HHS000663700275 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR YOUTH A. Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral- health-services-providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; Outpatient Treatment Services 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Supportive Residential Treatment Services 3. Intensive Residential Treatment Services B. TREATMENT FOR YOUTH (TRY) Program Target Population

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700022 Signature SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇, DrPH Assistant Deputy Commissioner ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor County Judge Date of Execution: September 3July 29, 2020 Date of Execution: Augusk 31July 29, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700022 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700268 HEALTH AND HUMAN SERVICES COMMISSION HOMEWARD BOUND, INC. ▇▇▇▇▇ Ita Associate Commissioner ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Executive Director Date of Executionexecution: September 3_August 4, 2020 Date of Executionexecution: Augusk 31August 4, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700268 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇’S PROPOSAL FOR SOLICITATION NO. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700265 HEALTH AND HUMAN SERVICES COMMISSION HOMEWARD BOUND, INC. ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH Date of execution: _August 11, 2020 ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Executive Director Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31August 11, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700265 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/behavioral-health-provider-resources/utilization-management-guidelines-manual, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700242 HEALTH AND HUMAN SERVICES COMMISSION CENIKOR FOUNDATION Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssoc. Commissioner IDD/BH President/CEO Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 23, 2020 Date of Executionexecution: Augusk 31July 23, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700242 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR HHSC CONTRACT NO. HHS000663700223 HEALTH AND HUMAN SERVICES COMMISSION NEXUS RECOVERY CENTER, INC. ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ PhoneExecutive Director/CEO Date of execution: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY July 24, 2020 Date of execution: July 23, 2020 THE FOLLOWING ATTACHMENTS TO HHSC CONTRACT NO. HHS000812700039 SYSTEM AGENCY HHS000663700223 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE Signature Printed Name: ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT ’S PROPOSAL FOR SOLICITATION NO. HHS000812700039 ARE INCORPORATED BY REFERENCEHHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will:TREATMENT FOR YOUTH A. Enhance laboratory testing and reporting capacity: Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-The below service types/levels of care are based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the on Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on (TAC) requirements, as referenced in the report template to be provided by Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to following link: ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral- health-services-providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; Outpatient Treatment Services 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Supportive Residential Treatment Services 3. Intensive Residential Treatment Services B. TREATMENT FOR YOUTH (TRY) Program Target Population

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: HHS000663700214 HEALTH AND HUMAN SERVICES COMMISSION Human Services of Southeast Texas, DBA ▇▇▇▇▇ Ita Associate Commissioner Date of execution: _July 20, 2020 ▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700214 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇▇@’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOWS A. CONTRACT INFORMATION Vendor ID: 17416841983 Grantee Name: Human Services of Southeast Texas, DBA Spindletop MHMR Contract Number: HHS000663700214 Contract Type Treatment Payment Method: Fee-for-Service DUNS Number: 87734489 Federal Award Identification Number (▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” ) B08TI083054-01 Solicitation Document: Health and the name of the attached file for all reports should be clearly identified with the Grantee’s NameHuman Services RFA# HHS0006637, Contract NumberSubstance Use Disorder Treatment, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20posted on February 7, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used forB. SERVICE AREA: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR HHSC CONTRACT NO. HHS000663700276 HEALTH AND HUMAN SERVICES COMMISSION PHOENIX HOUSES OF TEXAS, INC. ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ PhoneAssoc. Commissioner IDD/BH Title: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY President & CEO Date of execution: _August 11, 2020 Date of execution: August 10, 2020 THE FOLLOWING ATTACHMENTS TO HHSC CONTRACT NO. HHS000812700039 SYSTEM AGENCY HHS000663700276 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE Signature Printed Name: ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT ’S PROPOSAL FOR SOLICITATION NO. HHS000812700039 ARE INCORPORATED BY REFERENCEHHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will:TREATMENT FOR YOUTH A. Enhance laboratory testing and reporting capacity: Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-The below service types/levels of care are based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the on Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on (TAC) requirements, as referenced in the report template to be provided by Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to following link: ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral- health-services-providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; Outpatient Treatment Services 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Supportive Residential Treatment Services 3. Intensive Residential Treatment Services B. TREATMENT FOR YOUTH (TRY) Program Target Population

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700073 HEALTH AND HUMAN SERVICES COMMISSION CAREER & RECOVERY RESOURCES, INC. Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssoc. Commissioner IDD/BH CEO Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 19, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700073 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 078377909 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: State Opioid Response, 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, Program Official, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Email: ▇▇▇▇ ▇▇.▇▇▇▇@▇▇▇▇▇▇▇ .▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇HHS000779800004 HEALTH AND HUMAN SERVICES COMMISSION NORTH TEXAS BEHAVIORAL HEALTH AUTHORITY _ _ _ ▇▇▇▇▇ ▇▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Assoc. Commissioner Program Direckor Date of Execution: September 3IDD/BH CEO August 31, 2020 Date of Executionsignature: Augusk Date of signature: August 31, 2020 THE FOLLOWING ATTACHMENTS DOCUMENTS ARE ATTACHED TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000779800004 AND THEIR TERMS ARE HEREBY INCORPORATED INTO THE CONTRACT BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENT ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - CONTRACT AFFIRMATIONS VERSION 1.6, NOVEMBER 7, 2019 ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE VERSION 2.16.1, MARCH 26, 2019 ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT GOVERNMENTAL ENTITY VERSION, OCTOBER 23, 2019 ATTACHMENT I - SECURITY H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND PRIVACY INQUIRY TRANSPARENCY ACT (SPIFFATA) FORM ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.FOLLOW

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700132 HEALTH AND HUMAN SERVICES COMMISSION YSLETA DEL SUR PUEBLO ▇▇▇▇▇ Ita Associate Commissioner ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleGovernor Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 21, 2020 Date of Executionexecution: Augusk 31July 21, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700132 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700240 HEALTH AND HUMAN SERVICES COMMISSION ALIVIANE, INC. ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NOAssoc. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇Commissioner IDD/BH ▇▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke Title▇▇▇▇▇▇ ▇▇▇▇▇ Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700240 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇▇▇▇ , Grants Specialist, Contact Number: (▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇) ▇▇▇-▇▇▇▇ Phone▇, Facsimile: (▇▇▇) ▇▇▇-▇▇▇-▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed HHS000663700035 HEALTH AND HUMAN SERVICES COMMISSION ABILENE REGIONAL MHMR CENTER Name: ▇▇▇▇▇ Ita Name: ▇▇▇▇▇ ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssociate Commissioner CEO Date of execution: _Deputy Commissioner Program Direckor Date of Execution: September 3July 20, 2020 Date of Executionexecution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700035 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT GOV’T ENTITY VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700193 HEALTH AND HUMAN SERVICES COMMISSION THE COUNCIL ON RECOVERY ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke TitleAssoc. Commissioner IDD/BH Date of execution: _Deputy Commissioner Program Direckor July 20, 2020 President and CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: HHS000663700193 ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR FEMALES Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 H79TI081729 Federal Award Date: April 23, 2020 09/30/2018 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: State Opioid Response, 93.788 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 AtlantaOfficer, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: Point of Contact is ▇▇▇▇▇▇▇▇ ▇. Browne, Grants Specialist, Contact Number: (▇▇▇ Printed Name▇) ▇▇▇-▇▇▇▇, Email: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. The email “Subject Line” and the name HHS000663700138 HEALTH AND HUMAN SERVICES COMMISSION SOUTH TEXAS SUBSTANCE ABUSE RECOVERY SERVICES INC. ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH Date of the attached file for all reports should be clearly identified with the Grantee’s Nameexecution: _July 24, Contract Number2020 ▇▇▇▇▇ ▇▇▇ CEO Date of execution: July 23, IDCU/COVID and the month the report covers. C. May use funds to pay pre2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000663700138 ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak responseGRANTEE VERSION 2.16.1 ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I SYSTEM AGENCY SOLICITATION NO. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligibleHHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A MEDICATION ASSISTED TREATMENT

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700019 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Signature Printed Name: Title: Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700019 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700023 SYSTEM AGENCY GRANTEE Signature Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Printed Name: Hon ▇▇▇▇ _▇▇▇▇▇▇▇ Title: _County Judge Date of Execution: September 3August 16, 2020 Date of Execution: Augusk 31August 11, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700023 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow-up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to: those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this Contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e., population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR HHSC CONTRACT NO. HHS000663700208 HEALTH AND HUMAN SERVICES COMMISSION MHMR OF TARRANT COUNTY ▇▇▇▇▇ ▇▇▇▇▇▇ Assoc. Commissioner IDD/BH ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 AtlantaChief Executive Officer Date of execution: August 6, GA ▇▇▇▇▇-▇▇▇▇ Phone2020 Date of execution: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY August 3, 2020 THE FOLLOWING ATTACHMENTS TO HHSC CONTRACT NO. HHS000812700039 SYSTEM AGENCY HHS000663700208 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B PROGRAM SERVICES & UNIT RATES ATTACHMENT C GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS-GRANTEE Signature Printed Name: ATTACHMENT E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT F FEDERAL ASSURANCES AND CERTIFICATIONS ATTACHMENT G DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I HHSC SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor Date of Execution: September 3, 2020 Date of Execution: Augusk 31, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT ’S PROPOSAL FOR SOLICITATION NO. HHS000812700039 ARE INCORPORATED BY REFERENCEHHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will:TREATMENT FOR YOUTH A. Enhance laboratory testing and reporting capacity: Grantee shall provide Substance Use Disorder Treatment Services for one (1) or more of the following service types/levels of care. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-The below service types/levels of care are based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the on Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on (TAC) requirements, as referenced in the report template to be provided by Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to following link: ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral- health-services-providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; Outpatient Treatment Services 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.Supportive Residential Treatment Services 3. Intensive Residential Treatment Services B. TREATMENT FOR YOUTH (TRY) Program Target Population

Additional Grant Information. DSHS Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 B08TI083054-01 Federal Award Date: April 23, 2020 10/01/2019 Name of Federal Awarding Agency: Centers for Disease Control Department of Health and Prevention Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) CFDA Name and Number: 93.959 Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Grants Management Officer, Point of Contact is ▇▇▇▇▇ ▇▇▇▇, Grants Specialist, Contact Number: (▇▇▇) ▇▇▇-▇▇▇▇, Grants Management Officer Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇, Email: ▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇▇.▇▇▇.▇▇▇ SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000663700228 HEALTH AND HUMAN SERVICES COMMISSION VOLUNTEERS OF AMERICA TEXAS ▇▇▇▇▇ ▇Ita Associate Commissioner Date of execution: _July 20, 2020 ▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 SYSTEM AGENCY GRANTEE Signature Printed Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇ Printed Name: Signature Emi1y Everekke Title: _Deputy Commissioner Program Direckor CEO Date of Executionexecution: September 3, 2020 Date of Execution: Augusk 31July 20, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000663700228 ARE HEREBY INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT A-1 STATEMENT OF WORK SUPPLEMENTAL ATTACHMENT A-2 SUBSTANCE ABUSE PREVENTION AND TREATMENT (SAPT) BLOCK GRANT CONTRACT SUPPLEMENTAL ATTACHMENT B - BUDGET PROGRAM SERVICES & UNIT RATES ATTACHMENT C - GENERAL AFFIRMATIONS ATTACHMENT D UNIFORM TERMS AND CONDITIONS - GRANT CONDITIONS-GRANTEE ATTACHMENT D - SUPPLEMENTAL AND E SPECIAL CONDITIONS VERSION 1.2 ATTACHMENT E - F FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING AND CERTIFICATIONS ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT VERSION 8.5 ATTACHMENT H FISCAL FEDERAL FUNDING ACCOUNTABILITY AND TRANSPARENCY ACT (FFATA) FORM ATTACHMENT I - SECURITY SYSTEM AGENCY SOLICITATION NO. HHS0006637 INCLUDING ANY CLARIFICATIONS OR MODIFICATIONS MADE IN RESPONSE TO QUESTIONS SUBMITTED DURING POSTING AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I A, 1-4. Submit monthly reports by electronic mail to ▇▇▇▇▇.ANY ADDENDUM ATTACHMENT ▇ ▇▇▇▇▇▇▇’S PROPOSAL FOR SOLICITATION NO. HHS0006637 ATTACHMENTS FOLLOW ATTACHMENT A: STATEMENT OF WORK TREATMENT FOR ADULTS Grantee shall provide substance use disorder treatment services to the target population at one or more of the following service types/levels of care. The below service types/levels of care are based on Texas Administrative Code (TAC) requirements, as referenced in the Substance Use Disorder (SUD) Utilization Management (UM) Guidelines, located at the following link: ▇▇@▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” /doing-business-hhs/provider-portals/behavioral-health-services- providers/substance-use-disorder-service-providers, and American Society of Addiction Medicine (ASAM) criteria located at the name following link: ▇▇▇.▇▇▇▇.▇▇▇, which is a collection of the attached file for all reports should be clearly identified with the Grantee’s Name, Contract Number, IDCU/COVID objective guidelines that give clinicians a standardized approach to admission and the month the report coverstreatment planning. C. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.

Additional Grant Information. DSHS Grantee Data Universal Numbering System (DUNS) Number: 807391511 Federal Award Identification Number (▇▇▇▇): NU50CK000501 Catalog of Federal Domestic Assistance (CFDA) Name and Number (list all that apply): Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) – 93.323 Federal Award Date: April 23, 2020 Name of Federal Awarding Agency: Centers for Disease Control and Prevention Awarding Official Contact Information: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇-▇▇▇▇, Grants Management Officer ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ – Mailstop TV2 Atlanta, GA ▇▇▇▇▇-▇▇▇▇ Phone: ▇▇▇-▇▇▇-▇▇▇▇ SIGNATURE PAGE FOLLOWS SIGNATURE PAGE FOR SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700024 SYSTEM AGENCY GRANTEE Signature S g g Printed Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Title: _Assistant Deputy Commissioner Date of Execution: August 3, 2020 Printed Name: ▇▇▇▇▇ Printed Name: Signature Emi1y Everekke ▇▇▇▇▇▇▇ Title: _Deputy Commissioner Program Direckor Hays County Judge Date of Execution: September 3, 2020 Date of Execution: Augusk 31July _28, 2020 THE FOLLOWING ATTACHMENTS TO SYSTEM AGENCY CONTRACT NO. HHS000812700039 HHS000812700024 ARE INCORPORATED BY REFERENCE: ATTACHMENT A - STATEMENT OF WORK ATTACHMENT B - BUDGET ATTACHMENT C - UNIFORM TERMS AND CONDITIONS - GRANT ATTACHMENT D - SUPPLEMENTAL AND SPECIAL CONDITIONS ATTACHMENT E - FEDERAL ASSURANCES NON-CONSTRUCTION ATTACHMENT F - CERTIFICATION REGARDING LOBBYING ATTACHMENT G - FFATA ATTACHMENT H - HHS DATA USE AGREEMENT ATTACHMENT I - SECURITY AND PRIVACY INQUIRY (SPI) ATTACHMENTS FOLLOW I. GRANTEE RESPONSIBILITIES Grantee will: A. Establish or enhance ability to aggressively identify cases of COVID-19, conduct contact tracing and follow up activities, as well as implement recommended containment measures. 1. Enhanced contact tracing including contact elicitation/identification, contact notification, and contact follow-up. Activities could include traditional contact tracing methods as well as healthcare-specific methods. Other proximity/location-based methods using individuals’ cellphone tower data are not allowed to be used for the purposes of contact tracing. Information on contacts must be entered into the Texas Health Trace system in accordance with DSHS’s published guidance. B. Improve morbidity and mortality surveillance, including: 1. Establish or enhance community-based surveillance - Surveillance of populations and individuals includes but not limited to; those without severe illness, those with travel to high-risk locations, or those who are contacts to known cases. 2. Monitor and report daily COVID-19 probable and confirmed COVID cases (including deaths) to DSHS. 3. Track and send Emergency Department and outpatient visits for coronavirus (COVID)-like illness, as well as other illnesses, to Centers for Disease Control and Prevention (CDC). 4. Send copies of all admission, discharge, and transfer (ADT) messages to CDC National Syndromic Surveillance Program (NSSP). 5. Monitor and utilize available data in the CDC’s National Healthcare Safety Network (NHSN) for confirmed 2019 novel coronavirus (COVID-19) infection or for COVID-like illness. a. Long-term care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/ltc/covid19/index.html b. Acute care: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/nhsn/acute-care- hospital/covid19/index.html 6. Work with long-term care facilities to enroll the facility in the NHSN Long- term Care Facility (LTCF) COVID-19 Module. 7. Provide requested information on COVID-19 associated deaths to DSHS within three business days. C. Enhance laboratory testing and reporting capacity: 1. Establish or expand capacity to test all symptomatic individuals, and secondarily expand capacity to achieve community-based surveillance. This capacity would entail increasing testing capabilities above the current number of specimens that can be tested at the jurisdiction’s public health laboratory or by establishing new testing capabilities at the jurisdiction’s laboratory. 2. Screen for past infection (e.g., serology) for health care workers, employees of high-risk facilities, critical infrastructure workforce, and childcare providers. 3. Obtain all jurisdictional laboratory test data electronically, including from new, non-traditional testing settings, and using alternative file formats (e.g., .csv or .xls) to help automate. In addition to other reportable results, this should include all COVID-19 – related testing data, including all tests to detect severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) and serology testing. 4. Report all COVID-19 – related line level testing data (negatives, positives, indeterminants, serology) daily to DSHS. Data must meet new federal Coronavirus AID, Relief, and Economic Security (CARES) Act laboratory guidance. All public health data must be reported electronically to DSHS in compliance with the Texas Administrative Code and within appropriate reporting timeframes. B. D. Prevent and control COVID-19 in healthcare settings and protect other vulnerable or high-risk populations: 1. Assess and monitor COVID-19 infections in healthcare workers across the healthcare spectrum. 2. Perform infection control assessments using preparedness tools approved by DSHS to ensure interventions are in place to protect high-risk populations. 3. Monitor and help implement mitigation strategies for COVID-19 in all high- risk healthcare facilities (e.g., hospitals, dialysis clinics, cancer clinics, nursing homes, and other long-term care facilities, etc.). 4. Monitor and help implement mitigation strategies for other high-risk employment settings (e.g., meat processing facilities), and congregate living settings (e.g., prisons, youth homes, shelters). a. This includes coordinating with the Texas Department of Criminal Justice when individuals are released from serving their prison term and will be returning to the jurisdiction. These individuals may have been exposed to COVID-19 while in prison and/or may be COVID-positive and require additional public health follow-up. E. Monitor and mitigate COVID-19 introductions from connected jurisdictions (i.e., neighboring cities, states; including air travel). F. Work with healthcare system to manage and monitor system capacity. 1. Assess and monitor the number and availability of critical care staff, necessary PPE and potentially life-saving medical equipment, as well as access to testing services. 2. Leverage NHSN data to monitor healthcare worker staffing, Patient Impact, Hospital Capacity, and healthcare (PPE, PAPRs, ventilators, etc.) supplies. Grantee will request access to the NHSN database within 30 days of the execution of this contract or 30 days of hire for the position completing the data entry. Upon access approval, Grantee will review available NHSN data (at least monthly) to assess gaps in the healthcare system. G. Improve understanding of jurisdictional communities with respect to COVID-19 risk. Grantee must build an understanding of population density and high-risk population density (i.e. population of >65 yrs., proportion of population with underlying conditions, households with limited English fluency, healthcare seeking behavior, populations without insurance and those below poverty level). H. Submit a monthly report on the report template to be provided by the DSHS. Monthly reports are due on or before the 15th of each month. Each report must contain a summary of activities that occurred during the preceding month for each activity listed above in Section I AI, 1-4. A through G. Submit monthly reports by electronic mail to ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇▇▇▇.▇▇▇. The email “Subject Line” and the name of the attached file for all reports should be clearly identified with the Grantee’s Grantees Name, Contract Number, IDCU/COVID and the month the report covers. C. I. May use funds to pay pre-award costs which date back to January 20, 2020, that are directly related to the COVID-19 outbreak response. All pre-award costs must be approved in writing by DSHS. D. J. Not use funds for research, clinical care, fund raising activities, construction or major renovations, to supplant existing state or federal funds for activities, or funding an award to another party or provider who is ineligible. Other than normal and recognized executive-legislative relationships, no funds may be used for: 1. Publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body; 2. The salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative act or Executive order proposed or pending before any legislative body.